ArticleCureus2026
Drug Retention of First-Line Biologic Therapies in Rheumatoid Arthritis: Real-World Evidence From a Moroccan Cohort.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug retention is a meaningful real-world composite endpoint reflecting both long-term effectiveness and tolerability of biologic therapies in rheumatoid arthritis (RA). Data from North African cohorts remain scarce, and sociocultural determinants of treatment persistence are poorly explored. We conducted a retrospective observational study including RA patients who initiated first-line biologic therapy at a Moroccan tertiary center. Drug retention was defined as the time from initiation to permanent discontinuation for any reason. To compare drug retention across biologic agents, the Kaplan-Meier method was applied alongside the log-rank test. Cox proportional hazards regression was subsequently used to determine baseline factors independently associated with treatment discontinuation. One hundred and thirty patients met the inclusion criteria, with a clear female predominance (n = 112, 86.2%) and a mean age of 58.7 ± 12.9 years. Rituximab was the most frequently prescribed first-line biologic (n = 72, 56.1%), followed by Etanercept and Tocilizumab (n = 21, 16.2% each). Drug retention differed significantly across biologics (log-rank p = 0.018). Taking Adalimumab as the reference, three biologics showed significantly better retention: Etanercept (hazard ratio (HR) = 0.14, p = 0.001), Rituximab (HR = 0.26, p = 0.006), and Tocilizumab (HR = 0.07, p < 0.001). Additional independent predictors of better retention included concomitant conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy (HR = 0.39, p = 0.014), lower baseline Simplified Disease Activity Index (SDAI) (HR = 0.96, p = 0.020), and primary education level (HR = 0.32, p = 0.033). In this real-world Moroccan cohort, non-TNF (tumor necrosis factor) biologics demonstrated favorable retention compared to Adalimumab. Beyond treatment type, both clinical and sociocultural factors were associated with persistence. Given the retrospective observational design and the inherent risk of channeling bias, these results should be interpreted with appropriate caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.